Wednesday, September 21st
Targeting Angiotensin Receptor Signaling for Neuropathic Pain: Clinical Trials and the Development Landscape
Andrew Rice will guide the audience through the three published multicentre clinical trials that examined angiotensin receptor signaling for the treatment of neuropathic pain. He will contextualize the efficacy signals from the trials against the data from existing therapies for neuropathic pain. Rice A.S.C., Dworkin R.H., McCarthy T.D., Anand P., Bountra C., McCloud P.I., Hill J., Cutter G., Kitson, G., Desem, N. & Raff M. A novel target and treatment for post herpetic neuralgia: EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist studied in a double-blind, placebo-controlled, randomised phase2 clinical trial. The Lancet 2014;383:1637-1647 Rice ASC, Dworkin RH, Finnerup NB, Attal N, Anand P, Freeman R, Piaia A, Callegari F, Doerr C, Mondal S, Narayanan N, Ecochard L, Flossbach F & Pandhi S. Efficacy and safety of EMA401 in peripheral neuropathic pain: Results of two randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. PAIN 2021;162:2578-2589 .